Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using Toll-like receptor 7 agonist imiquimod as vaccine adjuvant

T cell-mediated immunity to microbes and to cancer can be enhanced by the activation of dendritic cells (DCs) via Toll-like receptors (TLRs). In this study, we evaluated the safety and feasibility of topical imiquimod, a TLR7 agonist, in a series of vaccinations (26) proteins,(27) and DNA, (28, 29)...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Adams, Sylvia, O'Neill, David W., Nonaka, Daisuke, Hardin, Elizabeth, Chiriboga, Luis, Siu, Kimberly, Cruz, Crystal M., Angiulli, Angelica, Angiulli, Francesca, Ritter, Erika, Holman, Rose Marie, Shapiro, Richard L., Berman, Russell S., Berner, Natalie, Shao, Yongzhao, Manches, Olivier, Pan, Linda, Venhaus, Ralph R., Hoffman, Eric W., Jungbluth, Achim, Gnjatic, Sacha, Old, Lloyd, Pavlick, Anna C., Bhardwaj, Nina
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2008
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2583094/
https://ncbi.nlm.nih.gov/pubmed/18566444
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi